Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 11/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932419 | 0.88 | TTK (0.67) | TTKJAK2JAK3PIK3CGPIK3CD | |
| SCHEMBL12507087 | 0.87 | TTK (0.63) | TTKJAK2PIK3CGERN1PIK3CD | |
| SCHEMBL1933117 | 0.85 | TTK (0.84) | TTKPIK3CGPIK3CDTDP2 | |
| SCHEMBL1933200 | 0.84 | JAK2 (0.62) | TTKJAK2JAK3ERN1UBE2N | |
| SCHEMBL1933365 | 0.84 | TTK (0.60) | TTKJAK2JAK3PIK3CGPIK3CD | |
| SCHEMBL1933919 | 0.83 | TTK (0.63) | TTKJAK2JAK3PIK3CGPIK3CD | |
| SCHEMBL1933198 | 0.83 | JAK2 (0.78) | TTKJAK2JAK3ERN1UBE2N | |
| SCHEMBL1932777 | 0.82 | TTK (0.62) | TTKJAK2JAK3PIK3CGPIK3CD | |
| SCHEMBL1934199 | 0.81 | TTK (0.84) | TTKPIK3CGPIK3CDPIK3CA | |
| SCHEMBL16290167 | 0.81 | TTK (0.60) | TTKJAK2JAK3PIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | claimed |
| EP-2507235-B1 | TRIAZOLOPYRIMIDINES | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | claimed |
| US-20120328610-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| EP-2343297-A1 | Triazolopyridines | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | claimed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-2507235-B1 | TRIAZOLOPYRIMIDINES | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2507235-B1 | TRIAZOLOPYRIMIDINES | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20120328610-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120328610-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2011063908-A1 | TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328610-A1 | TRIAZOLOPYRIDINES | TTBK1, BUB1, BUB1B | TTK 4/4885JAK2 1072/4885JAK3 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.